Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial.
A nice demonstration again in a placebo controlled trial that recombinant EPO is safe and effective in anemic cancer patients on chemorx. The three times weekly dose is more commonly […]
The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study.
An exciting issue is studied in this head/neck cancer patient population. Perioperative EPO may have a role to decrease blood transfusion needs and speed recovery. While this is only a […]
Recombinant human erythropoietin in pediatric oncology: a review.
Important to attempt review, but too much variability in studies to form meaningful conclusion. – Patricia Ford
The clinical value of erythropoietin in patients with cancer.
This is a good review of cancer- and chemotherapy-related anemia and its treatment with epoetin alfa. However, the review seems a bit negative regarding epoetin relative to blood transfusion when […]
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.
Published this month in Blood and the Journal of Clinical Oncology are the much discussed and debated guidelines of a blue ribbon panel on the evidence-based use of erythropoietin in […]
Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients.
The authors from Taiwan state that they used “Ferrum Hausmann, a ferric polymaltose complex.” Under the same name (Ferrum Hausmann), iron saccharate (identical to iron sucrose) has been licensed in […]